Figure 2.
Treatment of stroke with BMSCs, Niaspan and combination BMSCs+Niaspan all significantly increased SMI-31 (A, p < 0.05) expression compared to T1DM-MCAo control. Niaspan and combination BMSCs+Niaspan treatment both increased Synaptophysin (B, p < 0.05) expression in the ischemic brain compared to T1DM-MCAo control. Combination treatment additively increases Synaptophysin expression compared to BMSCs monotherapy rats (p < 0.05). Group number in T1DM-MCAo: n = 8; Niaspan-alone: n = 10; BMSCs-alone: n = 8; BMSCs + Niaspan: n = 7. * p < 0.05 vs. T1DM-MCAo control.